Viking Therapeutics, Inc. (VKTX)
NASDAQ: VKTX · Real-Time Price · USD
32.57
-1.14 (-3.38%)
At close: Jul 31, 2025, 4:00 PM
32.60
+0.03 (0.09%)
After-hours: Jul 31, 2025, 7:59 PM EDT

Company Description

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.

The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.

It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy.

The company was incorporated in 2012 and is headquartered in San Diego, California.

Viking Therapeutics, Inc.
Viking Therapeutics logo
CountryUnited States
Founded2012
IPO DateApr 29, 2015
IndustryBiotechnology
SectorHealthcare
Employees36
CEOBrian Lian

Contact Details

Address:
9920 Pacific Heights Boulevard, Suite 350
San Diego, California 92121
United States
Phone858 704 4660
Websitevikingtherapeutics.com

Stock Details

Ticker SymbolVKTX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001607678
CUSIP Number92686J106
ISIN NumberUS92686J1060
Employer ID46-1073877
SIC Code2834

Key Executives

NamePosition
Dr. Brian Lian Ph.D.President, Chief Executive Officer and Director
Gregory S. Zante CPA, CPAChief Financial Officer
Marianne ManciniChief Operating Officer
Michael MorneauVice President of Finance and Administration
Dr. Geoffrey E. Barker Ph.D.Chief Development Officer

Latest SEC Filings

DateTypeTitle
Jul 23, 202510-QQuarterly Report
Jul 23, 20258-KCurrent Report
Jul 3, 2025144Filing
Jul 3, 2025144Filing
Jul 3, 2025144Filing
May 27, 20258-KCurrent Report
May 12, 2025SCHEDULE 13G/AFiling
Apr 24, 202510-QQuarterly Report
Apr 23, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 23, 2025DEFR14AFiling